Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?:

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?: 887667 TAM0010.1177/1758835919887667Therapeutic Advances in Medical OncologyM Glas and S Kebir letter20192019 Therapeutic Advances in Medical Oncology Letter to the Editor Ther Adv Med Oncol Regorafenib in glioblastoma recurrence: 2019, Vol. 11: 1 –2 https://doi.org/10.1177/1758835919887667 DOI: 10.1177/ https://doi.org/10.1177/1758835919887667 how to deal with conflicting ‘real-life’ © The Author(s), 2019. Article reuse guidelines: experiences? sagepub.com/journals- permissions Martin Glas and Sied Kebir Correspondence to: To date, treatment options for glioblastoma recur- us to find an unusually high incidence of Martin Glas rence are scarce. Based on efficacy data from ran- Common Toxicity Criteria (CTC) grade 3 Division of Clinical Neurooncology, domized clinical trials, the nitrosourea compound adverse events to regorafenib in all but one Department of Neurology, CCNU (lomustine) is considered standard treat- patient. Among the most debilitating adverse University Hospital Essen, University Duisburg- ment after temozolomide failure. Treatment with events was a case of hand-foot-syndrome that Essen, Hufelandstr. 55, lomustine in recurrent glioblastoma yields did not respond to topical dermatological treat- 45147 Essen, Nordrhein- Westfalen, Germany median overall survival (mOS) ranging from 8.6– ment, and eventually led to the requirement for DKFZ-Division 9.8 months and median progression-free survival management with opioid analgesics to alleviate Translational 1–3 (mPFS) from 1.5–2.7 months. In a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Therapeutic Advances in Medical Oncology SAGE

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?:

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?:

Therapeutic Advances in Medical Oncology , Volume 11: 1 – Dec 16, 2019

Abstract

887667 TAM0010.1177/1758835919887667Therapeutic Advances in Medical OncologyM Glas and S Kebir letter20192019 Therapeutic Advances in Medical Oncology Letter to the Editor Ther Adv Med Oncol Regorafenib in glioblastoma recurrence: 2019, Vol. 11: 1 –2 https://doi.org/10.1177/1758835919887667 DOI: 10.1177/ https://doi.org/10.1177/1758835919887667 how to deal with conflicting ‘real-life’ © The Author(s), 2019. Article reuse guidelines: experiences? sagepub.com/journals- permissions Martin Glas and Sied Kebir Correspondence to: To date, treatment options for glioblastoma recur- us to find an unusually high incidence of Martin Glas rence are scarce. Based on efficacy data from ran- Common Toxicity Criteria (CTC) grade 3 Division of Clinical Neurooncology, domized clinical trials, the nitrosourea compound adverse events to regorafenib in all but one Department of Neurology, CCNU (lomustine) is considered standard treat- patient. Among the most debilitating adverse University Hospital Essen, University Duisburg- ment after temozolomide failure. Treatment with events was a case of hand-foot-syndrome that Essen, Hufelandstr. 55, lomustine in recurrent glioblastoma yields did not respond to topical dermatological treat- 45147 Essen, Nordrhein- Westfalen, Germany median overall survival (mOS) ranging from 8.6– ment, and eventually led to the requirement for DKFZ-Division 9.8 months and median progression-free survival management with opioid analgesics to alleviate Translational 1–3 (mPFS) from 1.5–2.7 months. In a

Loading next page...
 
/lp/sage/regorafenib-in-glioblastoma-recurrence-how-to-deal-with-conflicting-AXbM2k0ki0

References (8)

Publisher
SAGE
Copyright
Copyright © 2022 by SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
ISSN
1758-8340
eISSN
1758-8359
DOI
10.1177/1758835919887667
Publisher site
See Article on Publisher Site

Abstract

887667 TAM0010.1177/1758835919887667Therapeutic Advances in Medical OncologyM Glas and S Kebir letter20192019 Therapeutic Advances in Medical Oncology Letter to the Editor Ther Adv Med Oncol Regorafenib in glioblastoma recurrence: 2019, Vol. 11: 1 –2 https://doi.org/10.1177/1758835919887667 DOI: 10.1177/ https://doi.org/10.1177/1758835919887667 how to deal with conflicting ‘real-life’ © The Author(s), 2019. Article reuse guidelines: experiences? sagepub.com/journals- permissions Martin Glas and Sied Kebir Correspondence to: To date, treatment options for glioblastoma recur- us to find an unusually high incidence of Martin Glas rence are scarce. Based on efficacy data from ran- Common Toxicity Criteria (CTC) grade 3 Division of Clinical Neurooncology, domized clinical trials, the nitrosourea compound adverse events to regorafenib in all but one Department of Neurology, CCNU (lomustine) is considered standard treat- patient. Among the most debilitating adverse University Hospital Essen, University Duisburg- ment after temozolomide failure. Treatment with events was a case of hand-foot-syndrome that Essen, Hufelandstr. 55, lomustine in recurrent glioblastoma yields did not respond to topical dermatological treat- 45147 Essen, Nordrhein- Westfalen, Germany median overall survival (mOS) ranging from 8.6– ment, and eventually led to the requirement for DKFZ-Division 9.8 months and median progression-free survival management with opioid analgesics to alleviate Translational 1–3 (mPFS) from 1.5–2.7 months. In a

Journal

Therapeutic Advances in Medical OncologySAGE

Published: Dec 16, 2019

There are no references for this article.